The first company to go after human disease with a more precise genome-editing tool called base editing, Beam Therapeutics, launched today.
The technology: DNA is made up of lots of combinations of base letters (we know them as A, C, G, and T). Base editing, developed by Harvard chemical biologist and Beam cofounder David Liu, is designed to target just one base out of billions within the genome.
CRISPR 2.0: The traditional CRISPR system cuts a whole gene—a sequence of different base letters—to make a break in DNA’s double-helix structure. Liu’s base editors directly convert a single base into another, changing the gene from the mutated to the corrected form. Last year, researchers in China reported that they used base editing to snip disease out of a human embryo, but the approach hasn’t been tried in a person yet.
Treating disease: Beam, which is also cofounded by CRISPR pioneer Feng Zhang, hasn’t said what diseases it will focus on. But in a press release, it said that base editing could be used to treat some of the most devastating genetic disorders.
The first babies conceived with a sperm-injecting robot have been born
Meet the startups trying to engineer a desktop fertility machine.
Doctors have performed brain surgery on a fetus in one of the first operations of its kind
A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.
The FDA just approved rub-on gene therapy that helps “butterfly” children
Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.
Brain scans can translate a person’s thoughts into words
A new system was able to capture exact words and phrases from the brain activity of someone listening to podcasts.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.